Chronic Lymphocytic Leukemai (CLL), Non-Hodgkin's Lymphoma (Mantle cell lymphoma).
For NHL dose is 120mg/m2 IV, for CLL recommended dose is 100mg/m2 IV.
Known hypersensitivity to Bendamustine or mannitol.
Use Sterile Water for Injection, USP, for reconstitution and then either 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP for dilution, as outlined above. No other diluents have been shown to be compatible. Myelosuppression : May warrent treatement delay or dose reduction. Monitor closely and restart treatment based on ANC and platelet count recovery. Infection, Infusion Reactions and Anaphylaxis. Tumor Lysis Syndrome: May lead to acute renal failure and
Most common non-hematologic adverse reactions for CLL are pyrexia, nausea, and vomiting. Most common non-hematologic adverse reaction for NHL are nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decrease, dyspnea, rash, and stomatitis. Most common hematologic abnormalities for both indications are lymphopenia, anemia, leukopenia, thrombocytopenia, and neutropenia.
Concomitant CYP1A2 inducers or inhibitors have the potential to affect the exposure of Bendamustaine.